Pacira Reports Record Fourth Quarter and Full-Year Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pacira Pharma (PCRX) Tops Q4 EPS by 12c, Revenue Beats; Offers FY20 Revenue Guidance
February 20, 2020 8:05 AM ESTPacira Pharma (NASDAQ: PCRX) reported Q4 EPS of $0.56, $0.12 better than the analyst estimate of $0.44. Revenue for the quarter came in at $122.4 million versus the consensus estimate of $121.28 million.
2019 Full-Year and Fourth Quarter Financial Highlights
Full-year revenues of $421.0 million and fourth quarter revenues of $122.4 million.Full-year EXPAREL® (bupivacaine liposome injectable suspension) net product sales of $407.9 million and fourth quarter EXPAREL net product sales of $116.9 million.Full-year iovera° net product sales were $7.9 million and fourth quarter iovera° net product sales of $3.2 million. Pacira began recognizing sales of iovera° in April 2019 after completing its... More